Эффективность бета-адреноблокаторов и ингибиторов ангиотензинпревращающего фермента при нестабильной стенокардии, сочетанной с сахарным диабетом 2-го типа
![Диссертация: Эффективность бета-адреноблокаторов и ингибиторов ангиотензинпревращающего фермента при нестабильной стенокардии, сочетанной с сахарным диабетом 2-го типа](https://westud.ru/work/3463325/cover.png)
Научная новизна. У больных с НС, сочетанной с СД 2 типа, впервые установлены различия во влиянии исследованных бета-адреноблокаторов на систолическую и диастолическую функции ЛЖ, каждую из которых улучшал только карведилол. Метопролол CR/XL и бисопролол повышали фракцию выброса ЛЖ, не изменяя его диастолическую функцию. Атенолол не вызывал существенных изменений систолической и диастолической… Читать ещё >
Содержание
- Список используемых сокращений
- Общая характеристика работы (введение)
- Глава 1. Нестабильная стенокардия и особенности лечения сердечно-сосудистой патологии у больных с сахарным диабетом (обзор литературы)
- 1. 1. Нестабильная стенокардия: патофизиология, диагностика, современные возможности лечения
- 1. 2. Патогенез и течение ишемической болезни сердца у больных сахарным диабетом
- 1. 3. Особенности лечения и профилактики ишемической болезни сердца при сахарном диабете
- 1. 4. Резюме
- Глава 2. Материал и методы исследования
- 1. 1. Клиническая характеристика больных
- 1. 2. Методы исследования
Глава 3. Изменения параметров эхокардиографии, липидного, углеводного обмена и сердечно-сосудистые осложнения у больных с нестабильной стенокардией на фоне сахарного диабета 2 типа при лечении бета-адреноблокаторами.
3.1. Результаты лечения метопрололом CR/XL.
3.2. Результаты лечения бисопрололом.
3.3. Результаты лечения карведилолом.
3.4. Резюме.
Глава 4. Изменения параметров эхокардиографии, липидного, углеводного обмена и сердечно-сосудистые осложнения у больных с нестабильной стенокардией на фоне сахарного диабета 2 типа при лечении ингибиторами ангиотензинпревращающего фермента.
4.1. Результаты лечения каптоприлом.
4.2. Результаты лечения периндоприлом.
4.3. Резюме.
Глава 5. Изменения параметров эхокардиографии, липидного, углеводного обмена и сердечно-сосудистые осложнения у больных с нестабильной стенокардией на фоне сахарного диабета 2 типа при лечении комбинацией бисопролола с периндоприлом.
5.1. Результаты лечения комбинацией бисопролола с периндоприлом.
5.2. Резюме.
Глава 6. Обсуждение.
Выводы.
Список литературы
- Агеев Ф.Т., Мареев В. Ю., Лопатин Ю. М., Беленков Ю. Н. Роль различных клинических, гемодинамических и нейрогуморальных факторов в определении тяжести хронической сердечной недостаточности // Кардиология. — 1995. — № 11. — С. 4−12.
- Агеев Ф.Т., Овчинников А. Г., Мареев В. Ю., Беленков Ю. Н. Как лечить диастолическую дисфункцию сердца? // Consilium Medicum. 2002. — № 4. -С. 114−117.
- Алехин М.Н., Седов В. П. Допплер-эхокардиография в оценке диастолической функции левого желудочка // Тер. архив. 1996. — № 12. -С. 84−88.
- Балаболкин М.И., Клебанова Е. М., Креминская В. М. Патогенез и механизмы развития ангиопатий при сахарном диабете // Кардиология. -2000.-№ 10.-С. 74−87.
- Балаболкин М.И., Клебанова Е. М., Креминская В. М. Дифференциальная диагностика и лечение эндокринных заболеваний: Руководство. М.: Медицина, 2002. — 752 с.
- Барац С.С., Закроева А. Г. Диастолическая дисфункция сердца по показателям трансмитрального кровотока и потока в легочных венах: дискуссионные вопросы патогенеза, терминологии и классификации // Кардиология. 1998. — № 5. — С. 69−73.
- Беленков Ю.Н., Мареев В. Ю., Скворцов А. А. и др. Эналаприл против Карведилола. Сравнительное рандомизированное исследование у больныхс хронической сердечной недостаточностью (ЭКСТАЗ) // Сердечная недостаточность. 2001. — № 2. — С. 84−91.
- Беленков Ю. Н, Мареев В. Ю, Арутюнов Г. П, Агеев Ф. Т. Национальные рекомендации по диагностике и лечению ХСН // Сердечная недостаточность. 2003. — № 6. — С. 276−297.
- Ю.Белов Ю. В, Вараксин В. А. Постинфарктное ремоделирование левого желудочка сердца. М.: Де-Ново, 2002. — 194 с.
- П.Белов Ю. В, Вараксин В. А. Структурно-геометрические изменения миокарда и особенности центральной гемодинамики при постинфарктном ремоделировании левого желудочка // Кардиология. 2003. — № 1. — С. 1923.
- Гланц С. Медико-биологическая статистика: Пер. с англ. М.: Практика, 1999.-459 с.
- Грацианский Н.А. К выходу рекомендаций Всероссийского научного общества кардиологов «Лечение острого коронарного синдрома без стойких подъемов сегмента ST на ЭКГ» // Кардиология. 2002. — № 1. — С. 4−14.
- Грацианский Н.А. Эноксапарин как средство лечения острых коронарных синдромов без подъемов сегмента ST не превзошел нефракционированный гепарин. А фаза исследования A to Z // Кардиология. 2003. — № 6. — С. 70−71.
- Грацианский Н.А. Рекомендации по лечению острого коронарного синдрома без стойкого подъема сегмента ST на ЭКГ // Кардиология. -2004. № 4. — Приложение. — С. 4−28.
- Грацианский Н.А. Сравнение интенсивного и умеренного снижения уровней липидов статинами после острого коронарного синдрома // Кардиология. 2004. — № 4. — С. 85−87.
- Дедов И.И., Бондаренко И. З., Соляник Ю. А., Александров А. А. Метаболические эффекты небиволола у больных инсулиннезависимым сахарным диабетом // Кардиология. 2001. — № 5. — С. 35−37.
- Дедов И.И. Диабет как фактор риска сердечно-сосудистых заболеваний // Сердечная недостаточность. 2003. — № 1. — С. 15−16.
- Карпов Ю.А. Клинические последствия ингибирования тканевого ангиотензинпревращающего фермента: целесообразность при стабильной ИБС // Кардиология. 2002. — № 6. — С. 117−122.
- Козлов С.Г., Лякишев А. А. Дислипопротеинемии и их лечение у больных инсулиннезависимым сахарным диабетом // Кардиология. 1999. — № 8. -С. 59−67.
- Козлов С.Г., Лякишев А. А., Лобанова Т. Е., Ширяев А. А. Влияние сахарного диабета на результаты шунтирования коронарных артерий у больных ишемической болезнью сердца // Кардиология. 2001. — № 9. — С. 81−86.
- Мареев В.Ю. Ингибиторы ангиотензинпревращающего фермента в лечении больных коронарной болезнью сердца. Взгляд 2003 года // Кардиология. 2003. — № 12. — С. 4−14.
- Мартынов А.И., Васюк Ю. А., Копелева М. В., Крикунов П. В. Постинфарктное ремоделирование левого желудочка: возможности |3-адреноблокаторов // Кардиология. 2001. — № 3. — С. 79−83.
- Метелица В.И. Справочник по клинической фармакологии сердечнососудистых лекарственных средств. СПб.: Невский Диалект, 2002. — 926 с.
- Мычка В.Б., Горностаев В. В., Чазова И. Е. Сердечно-сосудистые осложнения сахарного диабета 2-го типа // Кардиология. 2002. — № 4. — С. 73−77.
- Овчинников А.Г., Агеев Ф. Т., Мареев В. Ю. Методические аспекты применения допплер-эхокардиографии в диагностике диастолической дисфункции левого желудочка // Сердечная недостаточность. 2000. — № 1.-С. 66−70.
- Остроумова О.Д., Ватутина"А.М, Зыкова А. А. Можно ли назначать бета-адреноблокаторы при сахарном диабете? // Consilium Medicum. 2002. — № З.-С. 136−139.
- Сидоренко Б.А., Преображенский Д. В. Бета-адреноблокаторы. М., 1996. -95 с.
- Терещенко С.Н., Демидова Н. В., Борисов Н. Е., Моисеев B.C. Клинико-гемодинамическая эффективность карведилола у больных застойной сердечной недостаточностью // Кардиология. 1998. — № 2. — С. 43−46.
- Трифонов И.Р. Биохимические маркеры некроза миокарда. Часть I. Общая характеристика биомаркеров. Их применение для диагностики инфаркта миокарда: обзор современных рекомендаций // Кардиология. 2001. — № 1. С. 93−98.
- Фейгенбаум X. Эхокардиография. / Пер. с англ. под ред. Митькова В. В. -М.: Видар, 1999.-512 с.
- Шестакова М.В. Проблема артериальной гипертонии при сахарном диабете // Кардиология. 1999. — № 6. — С. 59−65.
- Яфасов К.М., Дубянская Н. В. Дислипидемия при диабете II типа: патогенез и лечение // Кардиология. 2001. — № 9. — С. 74−77.
- Ahmed S.A., Manning D., McGurk С. et al. Multifactorial intervention and cardiovascular disease in type 2 diabetes // N. Engl. J. Med. 2003. — Vol. 348. -P. 1925−1927.
- American Diabetes Association. Management of dyslipidemia in adults with diabetes // Diabetes Care. 2002. — Vol. 25. — Suppl. — P. S74-S77.
- American Diabetes Association: Position Statement: Aspirin therapy in diabetes // Diabetes Care. 2003. — Vol. 26. — Suppl. 1. — P. S87-S88.
- American Diabetes Association: Position Statement: Management of dyslipidemia in adults with diabetes // Diabetes Care. 2003. — Vol. 26. — Suppl. l.-P. S83-S86.
- Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients // B.M.J. 2002. — Vol. 324. — P. 7186.
- Antman E.M., Cohen M., McCabe C. et al. Enoxaparin is superior to unfractionated heparin for preventing clinical events at 1-year follow-up of TIMIIIВ and ESSENCE // Eur. Heart J. 2002. — Vol. 23. — P. 308−314.
- Arauz-Pacheco C., Parrott M.A., Raskin P. The treatment of hypertension in adults patients with diabetes. Technical review // Diabetes Care. 2002. — Vol. 25. — P. 134−147.
- Arbustini E., Morbini P., Burke A.P. et al. Plaque erosion is a major substrate for coronary thrombosis in acute myocardial infarction // Heart. 1999. — Vol. 82. — P. 269−272.
- Battler A. European heart survey of acute coronary syndromes // Eur. Heart J. -2002.-Vol. 23.-P. 1190−1201.
- Behar S., Воуко V., Reicher-Reiss H., Goldbourt U. Ten-year survival after acute myocardial infarction: comparison of patients with and without diabetes // Am. Heart J. 1997.-Vol. 133.-P. 290−296.
- Berger A.K., Breall J.A., Gersh В.J. et al. Effect of diabetes mellitus and insulin use on-survival after acute myocardial infarction in the elderly (the Cooperative Cardiovascular Project) // Am. J. Cardiol. 2001. — Vol. 87. — P.272−277.
- Berlowitz D.R., Ash A.S., Hickey E.C. et al. Hypertension management in patients with diabetes: The need for more aggressive therapy // Diabetes Care. -2003. Vol. 26. — P. 355−359.
- Bertrand M.E., Simoons M.L., Fox K.A. et al. Management of acute coronary syndromes in patients without persistent ST-segment elevation // Eur. Heart J. -2002. Vol. 23. — P. 1809−1840.
- Betteridge D.J. Epidemiology of the cardiac complications of type 2 diabetes mellitus // Medicographia. 2001. — Vol. 23. — P. 95−99.
- Bjessmo S., Ivert Т., Flink H., Hammar N. Early and late mortality after surgery for unstable angina in relation to Braunwald class // Am. Heart J. 2001. — Vol. 141.-P. 9−14.
- Bloomgarden Z.T. Cardiovascular disease and diabetes // Diabetes Care. 2003. — Vol. 26. — P. 230−237.
- Boersma F. Harrington R. Moliterno D. et al. Platelet glycoprotein Ilb/IIIa inhibitors in acute coronary syndromes: A meta-analysis of all major randomised clinical trials // Lancet. 2002. — Vol. 359. — P. 189−198.
- Bristow M.R. B-Adrenergic receptor blockade in chronic heart failure // Circulation. 2000. — Vol. 101. — P. 558−569.
- Burke A.P.F.A., Tang A.L. Coronary risk factors and plaque morphology in men with coronary disease who died suddenly // N. Engl. J. Med. 1997. — Vol. 336.-P. 1276−1282.
- Campbell R.W.F., Turpie A.G.G., Maseri A. et al. Management strategies for a better outcome in unstable coronary artery disease // Clin. Cardiol. 1998. -Vol. 21. — P. 314−322.
- Campeau L. Grading of angina pectoris // Circulation. 1976. — Vol. 54. — P. 522−523.
- Candido R., Jandeleit-Dahm K., Nesteroff S. et al. Perindopril prevents atherosclerotic lesion development in diabetic apolipoprotein E knockout (ApoE) mice // J. Hypertens. 2002. — Vol. 20. — Suppl. 4. — P. S136.
- Capes S.E., Hunt D., Malmberg K., Gerstein H.C. Stress hyperglycemia and increased risk of death after myocardial infarction in patients with and without diabetes: a systematic overview // Lancet. 2000. — Vol. 355. — P. 773−778.
- CAPTURE I. Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE Study // Lancet. 1997. — Vol. 349. — P. 1429−1435.
- Cercek В., Shah P.K., Noc M. et al. For AZACS Investigators. Effect of short-term treatment with azythromycin on recurrent ischemic events in patients with acute coronary syndrome in the Azythromycin in Acute Coronary Syndrome
- AZACS) trial: a randomised controlled trial // Lancet. 2003. — Vol. 361. — P. 809−813.
- Chiariello L, Indolfi C. Silent myocardial ischemia in patients with diabetes mellitus // Circulation. 1996. — Vol. 93. — P. 2089−2091.
- Chobanian A. V, Bakris G. L, Black H.R. et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The JNC 7 Report // J.A.M.A. 2003. — Vol. 289. — P. 2560−2572.
- Chyun D, Vaccarino V, Murillo J. et al. Acute myocardial infarction in the elderly with diabetes // Heart Lung. 2002. — Vol. 31. — P. 327−339.
- CIBIS-II Investigators and Committees. The cardiac insufficiency bisoprolol study II (CIBIS II): a randomised trial // Lancet. 1999. — Vol. 353. — P. 9−13.
- Cohn J.N. Overview of the treatment of heart failure // J. Am. Coll. Cardiol. -1997.-Vol. 80.-P. 21−61.
- Cooper R. S, Pacold I. V, Ford E.S. Age-related differences in case-fatality rates among diabetic patients with myocardial infarction. Findings from
- National Hospital Discharge Survey, 1979−1987 // Diabetes Care. 1991. — Vol. 14. — P. 903−908.
- Copie X., Hnatkova K., Staunton A. et al. Predictive power of increased heart rate variability for risk stratification after myocardial infarction. Results of a 2-year follow-up study // J. Am. Coll. Cardiol. 1996. — Vol. 27. — P. 270−276.
- Cruickshank J.M. Beta-blockers continue to surprise us // Eur. Heart J. 2000. -Vol. 21.-P. 354−362.
- Davies M. Acute coronary thrombosis: the role of plaque disruption and its initiation and prevention // Eur. Heart J. 1995. — Vol. 16. — Suppl. L. — P. 3−7.
- Davies M. The composition of coronary artery plaque // N. Engl. J. Med. -1997. Vol. 336. — P. 1312−1313.
- Devereux R.B., Lutas E.M., Casale P.N. et al. Standartization of M-mode echocardiographic left ventricular anatomic measurement // J. Am. Coll. Cardiol. 1984. — Vol. 4. — P. 1222−1230.
- Devereux R.B., Alonso D.R., Lutas E.M. et al. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings // Am. J. Cardiol. 1986. — Vol. 57. — P. 450−458.
- Diaz R., Paolasso E.A., Piegas L.S. et al. Metabolic modulation of acute myocardial infarction. The ECLA (Estudios Cardiologicos Latinoamerica) Collaborative Group // Circulation. 1998. — Vol. 98. — P. 2227−2234.
- Diet F., Pratt R.E., Berry G.J. et al. Increased accumulation of tissue ACE in human atherosclerotic coronary artery disease // Circulation. 1996. — Vol. 94. -P. 2756−2767.
- Dzau V.J., Bernstein K., Celermaier D. et al. The relevance of tissue angiotensin-converting enzyme: manifestations in mechanistic and endpoint data // Am. J. Cardiol. 2001. — Vol. 88. — Suppl. L. — P. 1−20.
- Dzau V.J., Bernstein K., Celermajer D. et al. Pathophysiology and therapeutic importance of tissue ACE: a consensus report // Cardiovasc. Drugs. Ther. -2002.-Vol. 16.-P. 149−160.
- Ebbehoj E., Poulsen P.L., Hansen K.W. et al. Effects on heart rate variability of metoprolol supplementary to ongoing ACE-inhibitor treatment in Type I diabetic patients with abnormal albuminuria // Diabetologia. 2002. — Vol. 45. -P. 965−975.
- Egger T. Is ACE inhibitor the best first-line agent for diabetes with hypertension? // Diabetes Care. 2002. — Vol. 25. — P. 1488−1489.
- Ehmer В., van der Does R., Rudorf J. Influence of carvedilol on blood glucose and glycohaemoglobin Al in non-insulin-dependent diabetics // Drugs. 1988. -Vol. 36. — Suppl. 6. — P. 136−140.
- Eichorn E.J., Bristow M.R. Medical therapy can improve the biological properties of the chronically failing heart: a new era in the treatment of heart failure // Circulation. 1996. — Vol. 94. — P. 2285−2296.
- Eikelboom J.W., Anand S.S., Malmberg K. et al. Unfractionated heparin and low-molecular-weight heparin in acute coronary syndrome without ST elevation: a meta-analysis // Lancet. 2000. — Vol. 355. — P. 1936−1942.
- Elezi S., Kastrati A., Pache J. et al. Diabetes mellitus and the clinical and angiographic outcome after coronary stent placement // J. Am. Coll. Cardiol. -1998.-Vol. 32.-P. 1866−1873.
- Estacio R.O., Jeffers B.W., Hatt W.R. et al. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension // N. Engl. J. Med. 1998. — Vol. 338.-P. 645−652.
- European Society of Hypertension European Society of Cardiology guidelines of the management of arterial hypertension. Guidelines Committee // J. Hypertens. — 2003. — Vol. 21. — P. 1011−1053.
- Falk E., Shah P., Fuster V. Coronary plaque disruption // Circulation. 1995. — Vol- 92.- P. 657−671. ~ ------
- Farb A.B.A., Tang A.I. Coronary plaque erosion without rupture into a lipid core a frequent cause of coronary thrombosis in sudden coronary death // Circulation. 1996. — Vol. 93. — P. 1354−1363.
- Fath-Ordoubadi F., Beatt К J. Glucose-insulin-potassium therapy for treatment of acute myocardial infarction: an overview of randomized placebo-controlled trials // Circulation. 1997. — Vol. 96. — P. 1152−1156.
- Fattori R., Piva T. Drug-eluting stents in vascular intervention // Lancet. -2003. Vol. 361. — P. 247−249.
- Fava S., Azzopardi J., Muscat H.A., Fenech F.F. Factors that influence outcome in diabetic subjects with myocardial infarction // Diabetes Care. -1993.-Vol. 16.-P. 1615−1618.
- Feingold K.R., Grunfeld C., Pang M. et al. LDL subclass phenotypes and triglyceride metabolism in non-insulin-dependent diabetes // Arterioscler. Thromb. 1992. — Vol. 12. — P. 1496−1502.
- Ferguson J.J. NHLBI BARI clinical alert on diabetics treated with angioplasty // Circulation. 1995. — Vol. 92. — P. 3371−3376.
- Ferrari R., Angoletti L., Comini L. et al. Oxidative stress during myocardial ishaemia and heart failure // Eur. Heart J. 1998. — Suppl. В. — P. B2-B11.
- Fesmire F.M., Percy R.F., Bardoner J.B. et al. Usefulness of automated serial 12-lead ECG monitoring during the initial emergency department evaluation of patients with chest pain // Ann. Emerg. Med. 1998. — Vol. 31. -P.3−11.
- Feuerstein G.Z., Week P.K. Cardiac remodeling: from concepts to terapeutics // Heart Failure Reviews. 1999. — Vol. 4. — P. 7−19.
- Fisch C. The clinical ECG- sensitivity and specificity. Elsevier, 1997.
- Fogari R., Mugellini A., Zoppi A. et al. Effect of losartan and perindopril on plasma PAI-1 and fibrinogen in hypertensive type 2 diabetic patients // J. Hypertens. 1999. — Vol Л 7. — Suppl. 3. — P. 31 -34.
- Fogari R., Pasotti C., Zoppi A. et al. Effect of perindopril and atenolol on plasma PAI-1 in hypertensive patients with acute ischemic stroke // J. Hypertens. 2002. — Vol. 20. — Suppl. 4. — P. S145.
- Foo K., Sekhri N., Deaner A. et al. Effect of diabetes on serum potassium concentrations in acute coronary syndromes // Heart. 2003. — Vol. 89. — Vol. 31−35.
- Fuster V. Mechanisms leading to myocardial infaiction insights from studies of vascular biology // Circulation. 1994. — Vol. 90. — P. 2126−2146.
- Gaede P., Vedel P., Larsen N. et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes // N. Engl. J. Med. -2003.-Vol. 348.-P. 383−393.
- Galderisi M., Anderson K.M., Wilson P.W.F., Levy D. Echocardigraphic evidence for the existence of a distinct diabetic cardiomyopathy (The Framingham Heart Study) // Am. J. Cardiol. 1991. — Vol. 68. — P. 85−89.
- Galvani M., Ottani F. Ferrini D. et al. Prognostic influence of elevated values of cardiac troponin I in patients with unstable angina // Circulation.1997. Vol. 95. — P. 2053−2059.t
- Gerstein H.C. Epidemiology of heart disease in diabetes. In: Stanley W.C., Ryden L. editors. The Diabetic Coronary Patient. London: Science Press, 1999. -P. 3−12.
- Giannitsis E., Muller-Bardorff M., Kurowski V. et al. Independent prognostic value of cardiac troponin T in patients with confirmed pulmonary embolism // Circulation. 2000. — Vol. 102. — Vol. 211−217.
- Gottlieb S.S., McCarter R.J., Vogel R.A. Effect of beta-blockade on mortality among high risk and low-risk patients after myocardial infarction // N. Engl. J. Med. 1998. — Vol. 339. — P. 489−497.
- Granger С.В., Califf R.M., Young S. et al. Outcome of patients with diabetes mellitus and acute myocardial infarction treated with thrombolytic agents // J. Am. Coll. Cardiol. 1993. — Vol. 22. — P. 920−925.
- Gray R.P., Yudkin J.S., Patterson D.L. Enzymatic evidence of impaired reperfusion in diabetic patients after thrombolytic therapy for acute myocardial infarction // Br. Heart J. 1993. — Vol. 70. — P. 530−536.
- Gray R.S., Fabsitz R.R., Cowan L.D. et al. Risk factor clustering in the insulin resistance syndrome: the Strong Heart Study // Am. J. Epidemiol. -1998.-Vol. 148.-P. 869−878.
- Griendling K.K., Minieri C.A., Ollerenshow J.D. et al. Angiotensin II stimulates NADH and NADH oxydase activity in cultured vascular smooth muscle cells // Circ. Res. 1994. — Vol. 74. — P. 1141−1148.
- Grimm D., Jabusch H.C., Kossmehl P. et al. Experimental diabetes and left ventricular hypertrophy: effects of beta-receptor blockade // Cardiovasc. Pathol. -2002.-Vol. 11.-P. 229−237.
- Groenning B.A., Nilsson J.C., Sondergaard L. et al. Antiremodeling effects on the left ventricle during beta-blockade with metoprolol in the treatment of chronic heart failure // J. Am. Coll. Cardiol. 2000. — Vol. 36. — P. 2072−2080.
- Grundy S.M., Benjamin I.J., Burke G.L. et al. Diabetes and cardiovascular disease. A Statement for Healthcare Professionals from the American Heart Association // Circulation. 1999. — Vol. 100. — P. 1134−1146.
- GUSTO-IV ACS Investigators. Effect of glycoprotein llb/IIIa receptor blocker abciximab on outcome of patients with acute coronary syndromes without early revascularization: The GUSTO-IV ACS randomised trial // Lancet. 2001. — Vol. 357. — P. 1915−1924.
- Guyatt G. H, Sullivan MJ, Thompson PJ. et al. The 6-minute walk: a new measure of exercise capacity in patients with chronic heart failure // С. M. A. J. 1985.-Vol. 132.-P. 919−923.
- Haffner S. M, Lehto S, Ronnemaa T. et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction // N. Engl: J. Med. 1998. — Vol. 339. — P. 229−234.
- Haffner S.M. Coronary heart disease in patients with diabetes // N. Engl. J. Med. 2000. — Vol. 342. — P. 1040−1042.
- Hamm C. W, Braunwald E. A classification of unstable angina revisited // Circulation. 2000. — Vol. 102. — P. 118−122.
- Hansson L, Lindholm L. H, Niskanen L. et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril
- Prevention Project (САРР) randomized trial // Lancet. 1999. — Vol. 353. — P. 611−616.
- Hasdai D., Granger C.B., Srivatsa S.S. et al. Diabetes mellitus and outcome after primary coronary angioplasty for acute myocardial infarction: Lessons from the GUSTO-IIb angioplasty substudy // J. Am. Coll. Cardiol. 2000. -Vol. 35.-P. 1502−1512.
- Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lovering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial // Lancet. 2003. — Vol. 361. — P. 20 052 016.
- Held P.Y.S., Furberg C.D. Calcium channel blockers in acute myocardial infarction and unstable angina an overview // B.M.J. 1989. — Vol. 299. — P. 1187−1192.
- Herlitz J., Dellborg M., Karlson B.W. et al. Long-term mortality after acute myocardial infarction in relation to prescribed dosages of a beta-blocker at hospital discharge // Cardiovasc. Drugs Ther. 2001. — Vol. 14. — P. 589−595.
- Hjalmarson A. Cardioprotection with beta-adrenoceptor blockers. Does lipophilicity matter? // Basic. Res. Cardiol. 2000. — Vol. 95. — Suppl. 1. — P. 141−145.
- Hohnloser S.H., Franck P., Klingenheben T. et al. Open infarct artery, late potentials, and other prognostic factors in patients after acute myocardialinfarction in the thrombolytic era // Circulation. 1994. — Vol. 90. — P. 17 471 756.
- Holdaway I.M., Gamble G.D., Sanders G.A. et al. Effect of fosinopril on cardiac and metabolic parameters in patients with NIDDM // Diabetes Care. -1994. Vol. 17. — P. 1476−1479.
- Hostetter J.C., Ghaffari S. Q: Should everyone with a recent myocardial infarction receive a beta-blocker and an ACE inhibitor? // Cleve. Clin. J. Med. -2003.-Vol. 70.-P. 46−48.
- Hu F.B., Stampfer M.J., Haffner S.M. et al. Elevated risk of cardiovascular disease prior to clinical diagnosis of type 2 diabetes // Diabetes Care. 2002. -Vol. 25.-P. 1129−1134.
- Hypertension in Diabetic Study (HDS): Prevalence of hypertension in newly presenting type 2 diabetic patients and the association with risk factors for cardiovascular and diabetic complications // J. Hypertens. 1993. — Vol. 11. — P. 309−317.
- IONA Study Group. Effect of Nicorandil on coronary events in patients with stable angina the Impact Of Nicorandil in Angina (IONA) randomised trial // Lancet. 2002. — Vol. 359. — P. 1269−1275.
- Ishihara M., Sato H., Kawagoe T. et al. Impact of diabetes mellitus on long term survival after acute myocardial infarction in patients with single vessel disease//Heart.-2001.-Vol. 86.-P. 133−138.
- Jaffe A.S., Ravkilde J., Roberts R. et al. It’s time for a change to a troponin standard // Circulation. 2000. — Vol. 102. — P. 1216−1220.
- James S., Armstrong P., Califf R. et al. Safety and efficiency of abciximab combined with dalteparin in treatment of acute coronary syndromes // Eur. Heart J. 2002. — Vol. 23. — P. 1538−1545.
- Kaartinen M., van der Wai A., van der Loos C. Mast cell infiltration in acute coronary syndromes implications for plaque rupture // J. Am. Coll. Cardiol. -1998.-Vol. 32.-P. 606−612.
- Karlson B.W., Herlitz J., Hjalmarson A. Prognosis of acute myocardial infarction in diabetic and non-diabetic patients // Diabet. Med. 1993. — Vol. 10. p. 449−454.
- Kastrati A., Schomig A., Elezi S. et al. Predictive factors of restenosis after coronary stent placement // J. Am. Coll. Cardiol. 1997. — Vol. 30. — P. 14 281 436.
- Kendall M.J., Lynch K.P., Hjalmarson A., Kjekshus J. Beta-blockers and sudden cardiac death // Ann. Intern. Med. 1995. — Vol. 123. — P. 358−367.
- Khattar R.S., Senior R., Soman P. et al. Regression of left ventricular remodeling in chronic heart failure: Comparative and combined effects of captopril and carvedilol // Am. Heart J. 2001. — Vol. 142. — P. 704−713.
- King H., Aubert R., Herman W. Global burden of diabetes, 1995−2025: prevalence, numerical estimates, and projections // Diabetes Care. 1998. — Vol. 21.-P. 1414−1431.
- Kontny F. Reactivation of the coagulation system: rationale for long-term antithrombotic treatment // Am. J. Cardiol. 1997. — Vol. 80. — P. 55E-60E.
- Kwaan H.C. Abnormalities of hemostasis and fibrinolysis in diabetic patients with emphasis on coronary artery disease // Medicographia. 2001. -Vol. 23.-P.l 14−118.
- LaaksoM. Epidemiology of diabetic dyslipidemia // Diabetes Rev. 1995. -Vol. 3. — P. 408−422.к ?
- Lauer В., Niederau C., Kuhl U. et al. Cardiac troponin T in patients with clinically suspected myocarditis // J. Am. Coll. Cardiol. 1997. — Vol. 30. — P. 1354−1359.
- Lechat P.P., Escolano S., Golmard J.L. et al. Prognostic value of bisoprolol-induced hemodynamic effects in heart failure during the Cardiac Insufficiency Bisoprolol Study (CIBIS) // Circulation. 1997. — Vol. 96. — P. 2197−2205.
- Lechat P.P., Packer M., Chalon S. et al. Clinical effects of-adrenergic blockade in chronic heart failure: a meta-analysis of double-blind, placebo-controlled, randomized trials // Circulation. 1998. — Vol. 98. — P. 1184−1191.
- Leebeek F.W.G., Boersma E., Cannon C.P. et al. Oral glycoprotein Ilb/IIIa receptor inhibitors in patients with cardiovascular disease: why were the results so unfavourable // Eur. Heart J. 2002. — Vol. 23. — P. 444−457.
- Lee Т.Н., Cook E.F., Weisberg M. et al. Acute chest pain in the emergency room. Identification and examination of low-risk patients // Arch. Intern. Med. -1985.-Vol. 145.-P. 65−69.
- Libby P. Molecular basis of the acute coronary syndromes // Circulation. -1995. Vol. 91. — P. 2844−2850.
- Libby P. Cunent concepts of the pathogenesis of the acute coronary syndromes // Circulation. 2001. — Vol. 104. — P. 365−372.
- Lievre M., Gueyffier F., Ekbom T. et al. Efficacy of diuretics and beta-blockers in diabetic hypertensive patients: results from meta-analysis // Diabetes Care. 2000. — Vol. 23. — Suppl. 2. — P. B56-B71.
- Lindahl В., Venge P., Wallentin L. Relation between troponin T and the risk of subsequent cardiac events in unstable coronary artery disease. The FRISC study group // Circulation. 1996. — Vol. 93. — P. 1651−1657.
- Lindahl В., Diderholm E., Lagerqvist B. et al. Mechanisms behind the prognostic value of troponin T in unstable coronary artery disease: a FRISC II substudy // J. Am. Coll. Cardiol. 2001. — Vol. 38. — P. 979−986.
- Lindmark E., Diderholm E., Wallentin L., Siegbahn A. Relationship between interleukin 6 and mortality in patients with unstable coronary artery disease: effects of an early invasive or noninvasive strategy // J.A.M.A. 2001. -Vol. 286.-P. 2107−2113.
- Linen P. Biochemical mechanisms involved in the beta-blocker induced changes in serum lipoproteins //Am. Heart J. 1992. — Vol. 124. — P. 549−556.
- Lithell H.L. Effect of antihypertensive drugs on insulin, glucose and lipid metabolism // Diabetes Care. 1991. — Vol. 14. — P. 203−209.
- Lohmann F. W, Loesment W. A, Kaehler H. Beta-receptor blockade physical activity and metabolism // J. Cardivasc. Pharmacol. 1990. — Vol. 16. -Suppl 5. — P. S45-S52.
- Lowel H, Koenig W, Engel S. et al. The impact of diabetes mellitus on survival after myocardial infarction: can it be modified by drug treatment? // Diabetologia. 2000. — Vol. 43. — P. 218−226.
- Luchi R. J, Scott S. M, Deupree R.H. Comparison of medical and surgical treatment for unstable angina pectoris. Results of a Veterans Administration Cooperative Study // N. Engl. J. Med. 1987. — Vol. 316. — P. 977−984.
- Lyons T.J. Oxidized low density lipoproteins: a role in the pathogenesis of atherosclerosis in diabetes? // Diabetic Med. 1991. — Vol. 8. — P. 411−419.
- Мак K.-H, Moliterno D. J, Granger C.B. et al. Influence of diabetes mellitus on clinical outcome in the thrombolytic era of acute myocardial infarction // J. Am. Coll. Cardiol. 1997. — Vol. 30. — P. 171−179.
- Malmberg K, Yusuf S, Gerstein H.C. et al. Impact of diabetes on long-term prognosis in patients with unstable angina and non-Q-wave myocardial infarction // Circulation. 2000. — Vol. 102. — P. 1014−1019.
- McCarthy B.D., Wong J.B., Selker H.P. Detecting acute cardiac ischemia in the emergency department: a review of the literature // J. Gen. Intern. Med. -1990.-Vol. 5.-P. 365−373.
- McGill J.B., Schneider D.J., Arfken C.L. et al. Factors responsible for impaired fibrinolysis in obese subjects and NIDDM patients // Diabetes. 1994. -Vol. 43.-P. 104−109.
- MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF) // Lancet. 1999. — Vol. 353. — P. 2001−2007.
- Miami Trial research group. Metoprolol in myocardial infarction // Eur. Heart J. -1985. Vol. 6. — P. 199−226.
- Miettinen H., Lehto S., Salomaa V. et al. Impact of diabetes on mortality after the first myocardial infarction. The FINMONICA Myocardial Infarction Register Study Group // Diabetes Care. 1998. — Vol. 21. — P. 69−75.
- Missov E., Calzolari С., Pau B. Circulating cardiac troponin I in severe congestive heart failure // Circulation. 1997. — Vol. 96. — P. 2953−2958.
- Moreno P.R., Falk E., Palacios I.F. et al. Macrophage infiltration in acute coronary syndromes. Implications for plaque rupture // Circulation. 1994. -Vol. 90. — P. 775−778.
- Morris A.D., Boyle D.I., McMahon A.D. et al. and the DARTS/MEMO Collaboration. ACE inhibitor use is associated with hospitalization for severehypoglycemia in patients with diabetes // Diabetes Care. 1997. — Vol. 20. — P. 1363−1367.
- Morrow D.A., Antman E.M., Tanasijevic M. et al. Cardiac troponin I for stratification of early outcomes and the efficacy of enoxaparin in unstable angina: a TTMI-IIB substudy // J. Am. Coll. Cardiol. 2000. — Vol. 36. — P. 1812−1817.
- Motz W., Strauer B.E. Improvement of coronary flow reserve after long" term therapy with enalapril // Hypertension. 1996. — Vol. 27. — P. 1031−1038.i
- Moye L.A., Pfeffer M.A., Wun C.C. et al. Uniformity of captopril benefit in the SAVE Study: subgroup analysis. Survival and Ventricular Enlargement Study // Eur. Heart J. 1994. — Vol. 15. — Suppl. B. — P. 2−8.
- Mulder P., Elfertak L., Richard V. et al. Peripheral artery structure and endothelial function in heart failure: effects of angiotensin-converting enzyme inhibition // Am. J. Physiol. 1996. — Vol. 271. — P. H469-H477.
- Nathan D.M., Meigs J., Singer D.E. The epidemiology of cardiovascular disease in type 2 diabetes mellitus: How sweet it is. or is it? // Lancet. 1997. — Vol. 350. — Suppl. 1. — P. S4-S8.
- Negoro H., Morley J.E., Rosenthal M.J. Utility of serum fructosamine as a measure of glucemia in yong and old diabetic and non-diabetic subjects // Am. J. Med. 1988. — Vol. 85. — P. 360−364.
- Newby L.K., Ohman E.M., Christenson R.H. et al. Benefit of glycoprotein Ilb/IIIa inhibition in patients with acute coronary syndromes and troponin T-positive status: the paragon-B troponin T substudy // Circulation. 2001. — Vol. 103. — P. 2891−2896.
- Nichols G.A., Brown J.B. The impact of cardiovascular disease on medical care costs in subjects with and without type 2 diabetes // Diabetes Care. 2002. — Vol. 25. — P. 482−486.
- Niskanen L., Hedner Т., Hansson L. et al. ACE Inhibitor as one of several possible first-line agents is reasonable for diabetic patients with hypertension // Diabetes Care. 2002. — Vol. 25. — P. 1488−1489.
- Oler A., Whooley M.A., Oler J., Grady D. Adding heparin to aspirin reduces the incidence of myocardial infarction and death in patients with unstable angina. A meta-analysis // J.A.M.A. 1996. — Vol. 276. — P. 811−815.
- Opie L.H. Angiotensin-converting-enzyme inhibitors N.Y.: Autors' Publishing House, 1999. — 275 p.
- Ottani F., Galvani M., Nicolini F.A. et al. Elevated cardiac troponin levels predict the risk of adverse outcome in patients with acute coronary syndromes // Am. Heart J. 2000. — Vol. 140. — P. 917−927.
- Pahor M., Psaty B.M., Alderman M.H. et al. Therapeutic benefits of ACE inhibitors and other antihypertensive drugs in patients with type 2 diabetes // Diabetes Care. 2000. — Vol. 23. — P. 888−892.
- Pahor M., Psaty B.M., Alderman M.H. Furberg C.D. Meta-analysis of hypertension trials in diabetic patients: Response to parving and rossing // Diabetes Care. 2001. — Vol. 24. — P. 178−180.
- Palazzuoli A., Bruni F., Puccetti L. et al. Effects of carvedilol on left ventricular remodeling and systolic function in elderly patients with heart failure // Eur. J. Heart Fail. 2002. — Vol. 4. — P. 765−770.
- PARAGON-B investigators. Randomized placebo-controlled trial of titrated IV Lamifiban for acute coronary syndrome // Circulation. 2002. — Vol. 105. -P. 316−321.
- Passotti C., Zoppi A., Capra A. et al. Effect of beta-blockers on plasma lipids // Int. J. Clin. Pharmacol. Ther. Toxicol. 1986. — Vol. 24. — P. 448−452.
- Petrie J.R., Morris A.D., Ueda S. Trandolapril does not improve insulin sensitivity in patients with hypertension and type 2 diabetes: A double-blind, placebo-controlled crossover trial // J. Clin. Endocrinol. Metab. 2000. — Vol. 85. — P. 1882−1889.
- Psaty B.M., Heckbert S.R., Koepsell T.D. et al. The risk of myocardial infarction associated with antihypertensive drug therapies // J.A.M.A. 1995. -Vol. 274. — P. 620−625.
- Pyorala К., Laakso M., Uusitupa M. Diabetes and atherosclerosis: an epidemiologic view // Diabetes Metab. Rev. 1987. — Vol. 3. — P. 463−524.
- Rask-Madsen Ch., Ihlemann N., Krarup T. et al. Insulin therapy improves insulin-stimulated endothelial function in patients with type 2 diabetes and ischemic heart disease // Diabetes. 2001. — Vol. 50. — P. 2611−2618.
- Resnick H.E., Howard B.V. Diabetes and cardiovascular disease // Annu. Rev. Medicine. 2002: — Vol. 53: — P.245−267.
- Remme W.J., Swedberg K. Guidelines for the diagnosis and treatment of chronic heart failure // Eur. Heart J. 2001. — Vol. 22. — P. 1527−1560.
- Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus // Diabetes Care. 1998. — Vol. 21. — P. S5-S19.
- Ritter J.M., Chowienczyck P.J. Role of endothelial dysfunction in cardiovascular complications of diabetes mellitus // Medicographia. 2001. -Vol. 23.-P. 107−111.
- Rodrigues В., McNeil J.H. The diabetic heart: metabolic causes for the development of a cardiomyopathy // Cardivasc. Res. 1992. — Vol. 26. — P. 913 922.
- Roffi M., Chew D.P., Mukherjee D. et al. Platelet glycoprotein Ilb/IIIa inhibitors reduce mortality in diabetic patients with non-ST-segment-elevation acute coronary syndromes // Circulation. 2001. — Vol. 104. — P. 2767−2771.
- Ronnemaa Т., Laakso M., Kallio V. et al. Serum lipids, lipoproteins, and apolipoproteins and the excessive occurrence of coronary heart disease in non-insulin-dependent diabetic patients // Am. J. Epidemiol. 1989. — Vol. 130. — P. 632−645.
- Russel R.R., Yin R., Caplan M.J. et al. Additive effects of hyperinsulinemia and ishemia on myocardial GLUT1 and GLUT4 translocation in vivo // Circulation. 1998. — Vol. 98. — P. 2180−2186.
- Schwartzkopff В., Brehm M., Mundhenke M., Srauer B.E. Repair of coronary arterioles after treatment with perindopril in hypertensive heart disease // Hypertension. 2000. — Vol. 36. — P. 220−225.
- Secondary prevention by rasing HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the Bezafibrate Infarction Prevention (BIP) study // Circulation. 2000. — Vol. 102. — P. 21−27.
- Senior R., Basu S., Kinsey C. et al. Carvedilol prevents remodeling in patients with left ventricular dysfunction after acute myocardial infarction // Am. Heart J. 1999. — Vol. 37. — P. 646−652.
- Shepherd J. Fibrates and statins in the treatment of hyperlipidaemia: an appraisal of their efficacy and safety // Eur. Heart J. 1995. — Vol. 16. — P. 5−13.
- Silva J. A, Escobar A, Collins T.J. et al. Unstable angina. A comparison of angioscopic findings between diabetic and nondiabetic patients // Circulation. -1995.-Vol. 92.-P. 1731−1736.
- Silva J. A, Ramee S. R, White C.J. et al. Primary stenting in acute myocardial infarction: influence of diabetes mellitus in angiographic results and clinical outcome // Am. Heart J. 1999. — Vol. 138. — P. 446−455.
- Solomon C.G. Reducing cardiovascular risk in type 2 diabetes // N. Engl. J. Med. 2003: — Vob348. — P. 457−459.
- Stanley W. C, Lopaschuk G. D, McCormack J.G. Regulation of substrate metabilosm in the diabetic heart // Cardiovasc. Res. 1997. — Vol. 34. — P. 2533.
- Steiner G. Risk factors for macrovascular disease in type 2 diabetes. Classic lipid abnormalities // Diabetes Care. 1999. — Vol. 22. — Suppl. 3. — P. C6-C9.
- Stevens M. J, Raffel D. M, Allman K.C. et al. Cardiac sympathetic dysinnervation in diabetes implications for enhanced cardiovascular risk // Circulation. 1998. — Vol. 98. — P. 961−968.
- Summury of the Third Report of the National Cholesterol Education Program (NCEP). Expert Panel on Detection, Evaluation and Treatment of
- High Blood Cholesterol in Adults (Adult Treatment Panel III) // J.A.M.A. -2001. Vol. 285. — P. 2486−2497.
- Taegtmeyer H., McNulty P., Young M.E. Adaptation and maladaptation of the heart in diabetes: Part I: General concepts // Circulation. 2002. — Vol. 105. -P. 1727−1733.
- Takahashi N., Iwasaka Т., Sugiura T. et al. Left ventricular regional function after acute anterior myocardial" infarction in diabetic patients // Diabetes Care.1989.-Vol. 12.-P. 630−635.
- Taskiran M., Fritz-Hansen Т., Rasmussen V. et al. Decreased myocardial perfusion reserve in diabetic autonomic neuropathy // Diabetes. 2002. — Vol. 51.-P. 3306−3310.
- Tatti P., Guarisco R., Pahor M. et al. Outcome results of the fosinopril versus amlodipine cardiovascular events randomized trial (FACET) in patients with hypertension and NIDDM // Diabetes Care. 1998. — Vol. 21. — P. 597−603.
- Tavani A., Bertuzzi M., Gallus S. et al. Diabetes mellitus as a contributor to the risk of acute myocardial infarction // J. Clin. Epidemiol. 2002. — Vol. 55. -P. 1082−1087.
- Teichholtz L.E., Kreulen Т., Herman M.V., Gorlin R. Problems in echocardiographic volume determinations: echocardiographic-angiographic correlations in the presence at absence of asynergy // Am. J. Cardiol. 1976. -Vol. 37.-P. 7−11.
- The CAPRICORN Investigators. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial // Lancet. 2001. — Vol. 357. — P. 1385−1390.
- The EUROPA Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease (The EUROPA study) // Lancet. 2003. — Vol. 362. — P. 782−788.
- Theroux P., Waters D., Qiu S. et al. Aspirin versus heparin to prevent myocardial infarction during the acute phase of unstable angina // Circulation. -1993. Vol. 88. — P. 2045−2048.
- Theroux P., Fuster V. Acute coronary syndromes: unstable angina and non-Q-wave myocardial infarction // Circulation. 1998. — Vol. 97. — P. 1195−1206.
- The SOLVD Investigattors. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions // N. Engl. J. Med. 1992. — Vol. 327. — P. 685 691.
- Thybo N.K., Stephens N., Cooper A. et al. Effect of antihypertensive treatment on small arteries of patients with previously untreated essential hypertension//Hypertension. 1995. — Vol. 26. — P. 716−718.
- Toschi V.G.R., Lettino M., Fallon J.T. Tissue factor predicts the thrombogenicity of human atherosclerotic components // Circulation. 1997. -Vol. 95. — P. 594−599.
- Tuck M.L. Control of hypertension in diabetes // Diabetes Care. 2003. -Vol. 26. — P. 534−535.
- Turner R.C., Millns H., Neil H.A. et al. Risk factors for coronary artery disease in non-insulin-dependent diabetes melitus: United Kingdom Prospective Diabetes Study (UKPDS: 23) // B.MJ. 1998. — Vol. 316. — P. 823−828.
- Ubbink D.T., Verhaar E.E., Lie H.K., Legemate D.A. Effect of beta-blockers on peripherial skin microcirculation in hypertension and peripherial vascular disease // J. Vase. Surg. 2003. — Vol. 38. — P. 535−540.
- UK Prospective Diabetes Study (UKPDS) Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38 //В. M. J. 1998. — Vol. 317. — P. 703−713.
- Virmani R., Kolodgie F.D., Burke A.P. et al. Lessons from sudden coronary death a comprehensive morphological classification scheme for atherosclerotic lesions //Arteroscler. Thromb. Vase. Biol. 2000. — Vol. 20. — P. 1262−1275.
- Waagstein F., Bristow M.R., Swedberg K. et al. for the Metoprolol in Dilated Cardiomyopathy (MDC) Trial Study Group. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy // Lancet. 1993. — Vol. 342. -P. 1441−1446.
- Wei S., Chow L.T., Sanderson J.E. Effect of carvedilol in comparison with metoprolol on myocardial collagen postinfarction // J. Am. Coll. Cardiol. -2000. Vol. 36. — P. 276−281.
- White H.D. Should all patients with coronary disease resive angiotensin-converting-enzyme inhibitors? // Lancet. 2003. — Vol. 362. — P. 755−757.
- Wikstrand J., Berlund G., Hedblad В., Hulthe J. Antiatherosclerotic effects of beta-blockers // Am. J. Cardiol. 2003. — Vol. 91. — P. 25H-29H.
- Willenheimer R. Left ventricular remodeling and dysfunction. Can the process be prevented? // Int. J1 Cardiol. 2000. — Vol. 72. — P. .143−150.
- Willerson J.T.G.P., Eidt J., Campbell W.B., Buja M. Specific platelet mediators and-unstable coronary artery lesions: experimental evidence and potential clinical implications // Circulation. 1989. — Vol. 80. — P. 198−205.
- Wilson P.W.F., Anderson K.M., Kannel W.B. Epidemiology of diabetes mellitus in the eldery: the Framingham Offspring Study // Am. J. Med. 1986.- VoL 80r- Suppl. 5A. P: 3−9:
- Wu A.H., Apple F.S., Gibler W.B. et al. National Academy of Clinical Biochemistry Standards of Laboratory Practice: recommendations for the use of cardiac markers in coronary artery diseases // Clin. Chem. 1999. — Vol. 45. — P. 1104−1121.
- Yusuf S., Wittes J., Friedman L. Overview of results, of randomized clinical trials in heart disease. II. Unstable angina, heart failure, primary prevention with aspirin, and risk factor modification // J.A.M.A. 1988. — Vol. 260. — P. 2259−2263.
- Yusuf S., Zhao F., Mehta S.R. et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation //N. Engl. J. Med. 2001. — Vol. 345. — P. 494−502.
- Zhuo J.L., Mendelsohn F.A.O., Ohishi M. Perindopril alters angiotensin-converting enzyme, ATI receptor, and nitric oxide synthase expression in- patients with coronary heart disease // Hypertension. 2002. -«Vol. 39. — Part 2. -P. 634−638.
- Zonis В., Volkova N., Golubenkova N. The hypertensive therapy effects on lipoprotein metabolism by hypertensive patients with non-insulin depended diabetes mellitus // Atherosclerosis. 1997. — Vol. 134. — P. 385.
- Zuanetti G., Latini R., Maggioni A.P. Effect of the ACE inhibitor lisinopril on mortality in diabetic patients with acute myocardial infarction: data from the GISSI-3 study // Circulation. 1997. — Vol. 96. — 4239−4245.
- Российская Федерация Краснодарский край г. Краснодар Муниципальное учрездонма сдч -.сохранения Краен од j р.:.-. а и городская с:!:-«.- •-:.< 'wjji^rimu